^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Neuroendocrine Tumor
    Drug:pazopanib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Oncotarget
    Title:

    Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors

    Excerpt:
    ...Three GEP-NET patients with TP53 mutations demonstrated a durable response to pazopanib, either as PR or achievement of stable disease (Figure 2)…
    DOI:
    10.18632/oncotarget.6602